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Adjuvant chemotherapy for primary cardiac sarcomas:
the IGR experience
A Liombart-Cussac, X Pivot, G Contesso, A Rhor-Alvarado, JP Delord, M Spielmann, T TOrsz and A Le Cesne
Insttut Gustave Roussy, Vilejuif, France
Summary The effect of additional treatrnents after surgery in patients with primary cardiac sarcoma (PCS) remains unknown. The present
study aims to evaluate the benefit of chemotherapy in patients with non-metastatic cardiac sarcomas after optimal resection. Between
October 1979 and December 1995, 15 patients with a median age of 45 (range 16-66) and a resected primary cardiac sarcoma
[angk)sarcoma (six), mnalignant fibrous histiocytoma (three), leiomyosarcoma (two), rhabdomyosarcoma (two), liposarcoma (one) and
synoviosarcoma (one)] received a doxorubicin-containing regimen within 6 weeks of surgery. Adjuvant chemotherapy combinations included
cycophosphamide, vincristine and dacarbazine in fourpatients; ifosfamide in nine; methotrexate and vincristine in one; and doxorubicn alone
in one patient. At present, 13 patients have relapsed (five during therapy), with a median time to progression of 10 months. Twelve patients
developed local relapse, in four cases withut metastatic disease. Two patients remain in complete remission 27 and 25 months after surgery.
The median time to progression was shorter in patients presenting a cardiac angiosarcoma than other histological types (3 vs 14 months,
P < 0.01). Twelve patients have died, with a median overall survival of 12 months. The 2-year survival rate is 26%. Survival was significantly
klnger for patients with completely resected tumours (22 vs 7 months; P= 0.02) and those who did not have angiosarcom (18 vs 7 months;
P = 0.04). In conclusion, post-operative conventional doxorubecin-based chemotherapy failed to modify the natural history of patients with
resected cardiac sarcomras. Locoregional failure remains the main problem even after histologically complete resecton. New approaches
must be tested in patients with primary cardiac sarcomna.
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Primary cardiac sarcomas are extremely rare. They account for 8%
of all pnrmary cardiac tumours resected (Blondeau. 1990). but
the necroscopic incidence is threefold that of operated cases
(Chomette et al, 1985). All histological types have been described.
and angiosarcoma. representing 30-45% of cases. is the most
commonly described (McAllister et al. 1979: Silverman, 1980).
During the course of the disease, the presenting symptoms
(dyspnoea, chest pain, congestive heart failure, palpitations, fever.
or myalgia) appear late, and these delayed manifestations gener-
ally reflect a wide local extension with severe cardiac damage
(Goodwin. 1968). Even though distant metastasis frequently
occurs, the clinical course in patients with primary cardiac
sarcoma is related to local tumour extension (Becker et al. 1985).
Since the first surgical resection of a cardiac tumour was
reported (Crafoord, 1955). surgery has become the standard first-
line treatment, able to provide substantial palliation of symptoms
and prolong survival (Dein et al, 1987). However, most patients
present with marginally resectable or technically non-resectable
disease atdiagnosis, and patients surviving 2 years after local exci-
sion are rarely reported (Murphy et al. 1990: Moggio et al. 1992).
Given the likely inadequacy ofsurgical margins and the high risk
of distant metastasis, both adjuvant radiotherapy and systemic
chemotherapy have been recommended. Unfortunately. the results
Received21 August 1997
Revised 7May 1998
Accepted 19 May 1998
Coespdece tc, A omrbart-Cussac, Servio Oncobgia Medica, Insrtuto
Vanciano deOncolkoga C/P Beltran Baguena 9, Vaknca 46021, Spain
of these multimodality therapies are disappointing. In two recent
retrospective series (Putman et al. 1991: Burke et al. 1992). surgical
resection was the only factor found to improve survival, with a
suggested enhancement conferred by post-operative chemotherapy.
This study analyses the patterns of relapse and survival of 15
patients who have undergone resection of a primary cardiac
sarcoma. together with an adjuvant anthracycline-based chemo-
therapy regimen at the same institution.
MATERIAL AND METHODS
From October 1978 to December 1995. 19 patients were admitted
to our institution with an initial diagnosis of primary malignant
cardiac sarcoma. Patients were referred foradditional treatment by
French or Italian cardiovascular or thoracic institutions.
Histological diagnosis was made on the operative specimens
and all slides were reviewed by the pathology department of the
Institut Gustave Roussy. France. Diagnostic criteria excluded
patients with a history ofsoft-tissue orbone sarcoma. Surgery with
any macroscopic or microscopic involvement of margins was
classified as incomplete. Complete resection was defined by the
absence ofinvolvement ofall margins. The medical record ofeach
patient was reviewed and routine demographic data recorded until
1 March 1998. Lost follow-up information on two patients was
obtained by corresponding with their physicians.
Survival was calculated using the Kaplan-Meier method
(Kaplan and Meier, 1958). Groups were compared using the gener-
alized Wilcoxon-Gehan test (Gehan et al. 1965). All P-values
resulted from two-sided tests. Time to progression was calculated
from the date ofsurgical resection to the date offirst relapse. Time
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Table 1 Patient population
esection at Diseasetree
Patient Age initial Post-operativ survival Survival
no. (years) Sex Histoklgy surgery cmotherapy (months) Relapse (months) Status
1 39 M Lipo No AMV 4 L 5 D
2 50 F AS No CYVADIC 3 L+M 4 D
3 40 M AS No CYVADIC 3 M 5 D
4 16 M STS Yes Al 10 L+M 11 D
5 37 M AS No Al 6 M+L 12 D
6 57 M AS Yes Alc 12 M+L 22 D
7 66 F Leio No CYVADIC 5 L 10 D
8 28 M Rabdo Yesa CYVADIC + A 24 L+M 82 A,WMD
9 60 M AS No Al 1 L+M 2 D
10 46 M MFH No A 25 L 30 D
11 58 M MFH No Al 14 L+M 18 D
12 38 M AS No Al 4 L+M 7 D
13 51 F Leio Yest Al 11 L 13 D
14 43 M Rabdo Yes Al 27 - 27 A, NED
15 56 M MFH Yes Al 25 - 25 A, NED
aPatent had three resectons; bpatient had tworesectons; cradiaton therapy alsogiven. A, doxorubicin; Al, A + ifosfamide; CYVADIC, cyclophosphamide +
DTIC + A + vincristine; AMV, A + meotwexate + V; AS, angisrcoma MFH, malignant fbrous histiocytoma; Lipo, l*osarcoma; Leio, lei osarcoma; STS,
synovial sarcoma. M, metasatic progressn; L, local progression; D, dead; A, alive; WMD, with metastatic disease; NED, no evidence of disease.
to local failure was determined from the date of resection to the
date of local relapse. Survival was calculated from the date of the
first operation to the date oflast follow-up information.
RESULTS
Four patients with primary cardiac sarcoma (PCS) have been
excluded from the analysis. Two of these had an unresectable
tumour. suitable for biopsy only; death occurred 2 and 6 months
after diagnosis. The other two patients presented with synchronous
lung or cutaneous metastases. Local resection was complete in one.
but incomplete in the other. Neither patient responded to an anthra-
cycline-based chemotherapy regimen: in both cases the cause of
death was local progression 5 and 12 mWonths after surgery.
The characteristics of the remaining 11 male and four female
patients are listed in Table 1. The median age was 45 years (range
16-66). Six patients (40%) had an angiosarcoma. three a malig-
nant fibrous histiocytoma. two a leiomyosarcoma. two a rhabdo-
myosarcoma. and the remaining two had a liposarcoma and a
synovialsarcoma- The chamber of origin was associated with the
histological subtype: angiosarcoma commonly originated in the
right side of the heart (right atrium. n = 4; left atrium. n = 1; right
atrium and ventricle. n = 1). All the other histological types but
one developed on the left side of the heart (left atrium. n = 7: left
atrium and ventricle. n = 1: right atrium. n = 1). All patients
presented symptoms at diagnosis; cardiac manifestations varied
from chest pain to cardiac heart failure or constrictive pericarditis.
One patient developed a tumour embolus as the first symptom. A
patient with an implanted metallic mitral valve (patient 11) devel-
oped a malignant fibrous histiocytoma adjacent to this valve.
A complete resection was achieved in six patients. but was
incomplete in nine (four with microscopical residual disease and
five with gross residual tumour). Five out of six patients with an
angiosarcoma and four out of nine with other histological types
had incomplete resections.
After initial debulking surgery, all patients had a performance
status (PS) of 0-1 (PS 0. eight patients: PS 1. seven patients)
without severe congestive heart failure or obstructive symptoms.
documented by a normnal left ventricular ejection fraction (LVEF).
Three out of four patients with gross residual tumour. along with
seven other patients, underwent a chest scan or a cardiac magnetic
resonance examination before chemotherapy. Adjuvant
chemotherapy started within 6 weeks of surgery and included
(Table 1): cyclophosphamide. doxorubicin. vincristine and dacar-
bazine (CYVADIC regimen. n = 4): ifosfamide and doxorubicin
(Al regimen. n = 9): doxorubicin. methotrexate and vincristine
(AMV regimen. n = 1): and doxorubicine alone (n = 1). The mean
number of chemotherapy courses for the whole group was four
(range 1-6). Chemotherapy was stopped in one patient after three
cycles (cumulative doxorubicin dose 225 mg mr-) because of
impairment of LVEF. In five patients in whom resection was
incomplete. a local and/or distant recurrence was observed during
adjuvant chemotherapy. The nine patients who completed the
planned chemotherapy received a median doxorubicin cumulative
dose of 300 mg m-2 (range 250-360 mg m-2). Additional medi-
astinal adjuvant radiotherapy (50 Gy) was delivered to one patient
in whom surgical resection was incomplete.
Twelve patients (80%) developed local recurrence. which was
the first tumour event in eight of them. but in four was synchro-
nous with metastatic progression. The median disease-free interval
for local relapse was 11 months (range 1-25). Distant metastases
were observed in nine patients after a median time of 7 months
(range 1-65). The metastatic sites involved were the lung (n = 7).
soft tissue (n = 3). bone (n = 2). liver (n = 1). abdomen (n = 1) and
the central nervous system (n = 1). Only two patients were free of
disease at the time of analysis. with a follow-up of 25 and 27
months. The median disease-free progression interval (DFI) was
10 months (range 1-25).
Patients with primary cardiac angiosarcoma had a significantly
shorter DFI than patients with other histological types (P < 0.05):
the median DFI was 4 months (range 1-12) and 13 months (range
4-25) for vascular and non-vascular sarcoma respectively.
At the first sign ofrelapse. different palliative procedures were
implemented. Further chemotherapy regimens were administered
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in five patients with measurable lesions (five second-line and two
third-line regimens). One minor response (of less than 3 months)
and six cases of progressive disease were observed- No improve-
ment of symptoms was obtained with mediastinal radiotherapy in
four patients who had local progression. Two patients underwent
further surgery. One patient died during a heart transplant because
of local relapse. Finally, one patient with a primary cardiac rhab-
domyosarcoma obtained two remissions with local resections 24
and 43 months after the first surgical procedure; he developed a
metastatic recurrence 65 months later. which was also completely
resected. This young patient developed symptomatic congestive
heart failure (LVEF = 37%) after three cardiac resections and
450 mg m-2 ofdoxorubicin cumulative doses.
At the time of the analysis, 12 patients (80%) have died. The
cause of death was related to locoregional progression in 11. One
patient, who had no local recurrence, died of pulmonary metas-
tases 5 months after surgery. The median overall survival was 12
months (range 2-68). and the 2-year overall survival rate was 19%
(Figure 1).
Survival was significandly shorter in patients with angiosarcoma
than in the rest of the population (7 vs 18 months. P = 0.04) as
shown in Figure 2. The six patients with a completely resected
cardiac sarcoma had a significandly longer survival rate than the
nine with residual disease (Figure 3), with a median survival of22
months and 7 months respectively (P = 0.02).
DISCUSSION
Primary sarcoma ofthe heart is rare with a dismal short-term prog-
nosis. Surgery is the only treatment capable ofimproving outcome
even after palliative resection, but long-term survivors are still
anecdotal. Sporadic cases oflong-term survivors treated with radi-
ation therapy (Stevens et al. 1992) and/or chemotherapy (Potter et
al. 1989) have been reported. However, because of the small
number of patients. we do not know whether post-surgical treat-
ment can confer a gain in survival.
For common soft-tissue sarcomas. adjuvant anthracycline-
containing chemotherapy regimens seem to decrease the incidence
of local and metastatic relapse (Tiemey et al, 1995). Inadequate
resection margins, high-grade tumours and primary truncal
sarcomas are unfavourable independent prognostic factors
(Trojani et al, 1984) and they seem to be good indicators for adju-
vant chemotherapy. Mainly for these reasons, most authors have
recommended complementary chemotherapy with or without
radiotherapy in patients with resected PCS (Demny. 1996).
The goal ofthis retrospective study was to analyse the potential
benefit ofpost-operative doxorubicin-containing chemotherapy in
healthy patients with PCS having undergone local resection.
Patients with unresectable tumours. low performance status or any
contraindication to anthracyclines were excluded. Doxorubicin
was used in most cases combined with ifosfamide or dacarbazine.
two active regimrens in advanced soft-tissue sarcomas (Antman
et al, 1993; Edmonson et al. 1993; Santoro et al. 1995). Chemo-
therapy was started within 6 weeks of surgery. Thus, this series
represents a selected group ofPCS patients treated by surgery and
optimal chemotherapy. with a hypothetically more favourable
outcome than in any otherpublished study. Despite this. results are
disappointing. The median interval to first relapse (local or
metastatic) was 10 months and the median survival was 12
months. Only three patients were alive at the time ofanalysis. one
with metastatic disease. These results move towards those
obtained by another series (Putman et al, 1989) who achieved an
overall survival rate of 14% at 2 years in a less favourable popula-
tion, including patients with non-resected or untreated disease.
The type of sarcoma was the only histological finding corre-
lating with progression-free survival and overall survival. Patients
with cardiac angiosarcoma had the least favourable outcome
because all relapsed and died. 83% of them in the first year. None
of the published series stressed this point, but Putman et al (1989)
reported no surviving patients with angiosarcoma 18 months after
diagnosis as opposed to 42% (5 out of 12 patients) with other
histological types. In common sarcomas (visceral or soft tissue),
angiosarcomas have a poor prognosis irrespective of primary site
and histological grade. A retrospective analysis on 1100 patients
with resected sarcoma (Hashimoto et al. 1992) reported an overall
survival of 14% at 5 years for angiosarcoma. as opposed to 70%
for patients with myxoid liposarcoma. In PCS. a previous study
(Burke et al. 1991) demonstrated a relationship between histolog-
ical features, for example high mitotic activity or tumour necrosis
and dismal outcome.
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The quality of initial tumour debulking was predictive of a
disease-free and status survival in our study. One series (Putnam et
al. 1991) reported an overall survival of 24 months for patients
having undergone wide resection of tumours. compared with only
10 months in all otherpatients. Similarly. in the univariate analysis.
complete or wide excision was associated with an increased
survival in the Anned Forces Institute series (Burke et al. 1992)
The extent of the surgical procedure seemed related to histo-
logical type because angiosarcoma patients had more incomplete
resections (five out of six). whereas patients with non-vascular
sarcomas had more completely resected tumour (five out ofnine).
This point did not reach statistical significance probably because
of the small number of patients (P = 0.1). However. the relatively
high incidence ofpericardic involvement and multifocal presenta-
tion of angiosarcomas could partially account for the inadequate
local control ofthese tumours.
Local relapse was the first and most common type of recur-
rence. Only one patient. who died early because of pulmonary
metastases. had no local failure. However. distant metastases were
generally detected at the same time or a few months after local
recurrence. The same pattern of relapse is observed in patients
with marginally or incompletely resected high-grade soft-tissue
sarcomas (Choong et al. 1995: Lewis et al. 1997).
Primary cardiac sarcomas can be divided into two groups
according to the histological subtype. Cardiac angiosarcomas tend
to anse in the right chambers ofthe heart. thus delaying symptoms
(Janigan et al. 1986). They are initially larger tumours and carry a
poor prognosis whatever the quality of initial surgical resection.
which is generally incomplete (Potter et al. 1989). These factors.
compounded by the high frequency of distant metastasis at diag-
nosis (Herrmann et al. 1992). contribute to the limited duration of
survival. Moreover. these tumours are usually resistant to conven-
tional cytotoxic agents as observed in our patients. New effective
drugs. and innovative strategies such as inmunotherapy. antiangio-
genic factors or intensive chemotherapy regimens need to be
tested on these high-grade aggressive tumours.
In contrast. non-vascular cardiac sarcomas appear to be less
aggressive: they arise predominantly in the left chambers of the
heart and present as an intracavity mass. The most frequent cause
of relapse in our series was local progression. These tumours
should undergo optimal resection. and neoadjuvant chemotherapy
could be incorporated in treatment. Adjuvant radiotherapy seems
mandatory ifthe aim is topreclude local relapse. but the best option
for selected patients could be an orthotopic cardiac transplant.
In recent years. orthotopic heart transplant has been proposed to
only a few unselected patients with primary cardiac sarcoma
(Goldstein et al. 1995). namely patients with locally advanced
tumours (Siebenmann et al. 1990) orangiosarcoma (Armitage et al.
1990: Crespo et al. 1993). Most of these cases rapidly developed
distant metastases thereafter. and long-term survivors are still rare
(Aravot et al. 1989). Based on ourdata. hearttransplantation can be
proposed to patients with widely resected non-angiosarcoma
cardiac tumours with no obvious distant metastasis.
In conclusion and despite the dismal prognosis. abenefit in quality
oflife and sur ival has been observed overthe lastdecade in patients
with PCS. This improvement is based on (i) the routine use of
echocardiography. allowing a more accurate diagnosis: (ii) the devel-
opment ofnew surgical techniques which have improved the quality
and number of cardiac resections (Perchinsky et al. 1997): and.
perhaps. (iii) the optimization of chemotherapy regimens including
anthracyclins and high-dose ifosfamide (Le Cesne et al. 1996).
In the next years. oncologists will be concerned about additional
treatments in patients after optimal PCS resection. The impact of
conventional chemotherapy cannot be determined in this small and
retrospective study. but a need for more active systemic treatments
and/or new therapeutic approaches emerged from the outcome of
these patients.
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